Abstract: The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations.

Abstract: An adjustable front-opening hospital gown includes first and second front panels having respective mating fasteners, a rear panel, and an orientation feature such as a V-neck or other type of collar. The first front panel overlaps the second front panel in front of a torso of a patient. The rear panel is connected to the front panels, and defines an elongated slot that is overlapped or otherwise remains closed when access to a back of the patient is not required. The orientation feature identifies a designated front of the hospital gown. The gown may include intravenous access flaps, each positioned between the rear panel and a respective front panel. The rear panel may include first and second rear panels, one of which includes an edge overlapped by the other of the panel within the elongated slot to close the elongated slot.

Abstract: A front-opening hospital gown includes first and second front panels. The first front panel overlaps the second front panel when the gown is worn by a patient. The second front panel has fasteners in multiple columns and rows. The first front panel has mating fasteners, for instance a single column of multiple rows. The number of rows on the front panels may be equal. An additional rear panel(s) defines an elongated slot on the back of the gown for access to the patient's back. The gown may include an anti-microbial coating, colored fabric that indicates the size of the gown, an RFID tag, color-coded intravenous access flaps, and a telemetry pocket. The intravenous access flaps may have color-coded fasteners or backing twill material. The gown may include a collar indicating the front of the gown. The collar may have a contrasting color relative to a color of the panels.

Abstract: Thymosin ?4 can be used to treat neuronal and brain injuries that are accompanied by neuronal cell death or injury, including injuries caused by stroke or trauma and injuries caused by neurological and neurodegenerative disease. In particular, stroke and multiple sclerosis are examples of conditions which may be ameliorated by treatment with thymosin ?4. Thymosin ?4 has been found to restore neurological tissue through several effects on several neurological parameters which are improved by administration of thymosin ?4 to a subject in need of neurological tissue restoration. For example, thymosin ?4 improves axonal myelination, migration of neural progenitor cells, neural progenitor cell proliferation, differentiation of neural progenitor cells into mature neurons, differentiation of neural progenitor cells into mature glia, nerve regeneration, and brain remodeling at locations of brain injury.

Abstract: Without limitation, some embodiments comprise a method of treatment for promoting recovery of peripheral neuropathy in a subject, including administering to a subject in need of such treatment a therapeutically effective amount of a composition comprised of thymosin beta 4, amino acid sequences LKKTET or LKKTNT, and/or any conservative variants thereof, or an agent that stimulates production of any of those materials, or a conservative variant thereof.

Abstract: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.

Abstract: Some embodiments comprise methods, systems, and compositions to produce and/or administer modified exosomes or other vesicles containing one or more selected microRNAs, including but not limited to, miR-146b. Some embodiments also comprise the therapeutic administration and use of such modified exosomes and/or producer cells to treat mammalian injuries and diseases, including in human beings.

Abstract: A method for assessing whether a patient is at risk of developing a clinical condition includes receiving training data representing a set of patient-related variables for each of a plurality of patients; generating model data based on the received training data; receiving target data representing the set of patient-related variables for a target patient; determining a risk level for the target patient of developing the clinical condition; and indicating the risk level of the target patient, where the set of patient-related variables consists of a first set of variables when the clinical condition is a mortality condition and a second set of variables when the clinical condition is a morbidity condition.

Abstract: A device and method for determining intravascular pressure and irregular needle placement in a hemodialysis procedure include analyzing means for automatically deriving venous access pressure (VAP) at a location of venous needle insertion into the patient and determining a ratio of VAP to mean arterial pressure, where the analyzing means determines multiple VAP values over multiple time periods and determines multiple ratios, one for each VAP value. Detecting means compare each ratio to a predetermined standard ratio derived from a moving average of prior VAP ratios, where the detecting means detects irregular needle placement when elevation of the ratio above the standard ratio is indicated.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Abstract: The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).

Abstract: An injector for delivering an injectate into the myocardium of the heart may be implemented as a catheter or a handheld unit. The injector includes a body, a stabilizer secured to a distal end of the body, and a needle that may be controllably advanced from the distal end of the body. The stabilizer stabilizes the distal end of the body relative to the myocardium while the heart beats. An enlarged region disposed along the needle prevents the needle from being advanced into the myocardium beyond a desired penetration depth. To make an injection, the physician brings the distal end of the body in proximity to the myocardium, actuates the stabilizer to stabilize the distal end relative to the myocardium, and advances the needle into the myocardium. Advancement of the needle is impeded by the enlarged region, thereby placing the needle tip at the desired penetration depth for the injection.

Abstract: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.

Abstract: An injector for delivering an injectate into the myocardium of the heart may be implemented as a catheter or a handheld unit. The injector includes a body, a stabilizer secured to a distal end of the body, and a needle that may be controllably advanced from the distal end of the body. The stabilizer stabilizes the distal end of the body relative to the myocardium while the heart beats. An enlarged region disposed along the needle prevents the needle from being advanced into the myocardium beyond a desired penetration depth. To make an injection, the physician brings the distal end of the body in proximity to the myocardium, actuates the stabilizer to stabilize the distal end relative to the myocardium, and advances the needle into the myocardium. Advancement of the needle is impeded by the enlarged region, thereby placing the needle tip at the desired penetration depth for the injection.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Abstract: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.

Abstract: A device and method for determining intravascular pressure and irregular needle placement in a hemodialysis procedure include analyzing means for automatically deriving venous access pressure (VAP) at a location of venous needle insertion into the patient and determining a ratio of VAP to mean arterial pressure, where the analyzing means determines multiple VAP values over multiple time periods and determines multiple ratios, one for each VAP value. Detecting means compare each ratio to a predetermined standard ratio derived from a moving average of prior VAP ratios, where the detecting means detects irregular needle placement when elevation of the ratio above the standard ratio is indicated.

Abstract: Structurally supportive material is implanted or injected into cardiac veins as discrete masses at various sites in the cardiac venous system to reinforce the myocardium for the purpose of preventing, moderating, stopping or reversing negative cardiac remodeling due to various adverse cardiac conditions, both acute and chronic, or for the purpose of treating localize anomalies of the heart, or for both purposes. The sites may be arranged in a pattern about one or more chambers of the heart such that the masses cooperatively reduce stress in the chamber wall and reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function.